Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Tg Therapeutics, Inc.
A biopharmaceutical company focused on B-cell-driven diseases, most notably multiple sclerosis. Its main product, BRIUMVI (ublituximab), is an infusion approved by the US FDA in 2022 to treat relapsing forms of MS. The firm traces roots to 1993 but took the TG Therapeutics name around 2012 under biotech veteran Michael Weiss, and the "TG" initials are commonly tied to its founders.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
8.01 Other Events · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits